Chronic Lymphocytic Leukemia

Hill Compares Toxicity Profiles of Current Treatment Regimens in Relapsed CLL

September 24, 2020

During a Case Based Peer Perspectives event Brian T. Hill, MD, PhD, discussed the case of a 53-year-old patients with chronic lymphocytic leukemia.

Acalabrutinib Demonstrates Superior PFS Over Standard-0f-Care in Relapsed/Refractory CLL

September 12, 2020

Acalabrutinib sustained superiority in terms of extended progression-free survival with a tolerable safety profile in patients with relapsed/refractory chronic lymphocytic leukemia, which was inclusive of patients with high-risk features, results from the phase 3 ASCEND trial (NCT02970318) show.

FDA Grants Orphan Drug Designation to Novel Bcl-2 inhibitor in CLL

September 08, 2020

A novel Bcl-2 inhibitor, APG-2575, has been granted an Orphan Drug designation by the FDA for the treatment of patients with chronic lymphocytic leukemia.

Acalabrutinib Shows Promising Results for the Treatment of CLL

September 02, 2020

Jennifer Woyach, MD, discusses the rationale and efficacy for the phase 1/2 trial of acalabrutinib in patients with chronic lymphocytic leukemia.

Barr Evaluates BTK Inhibitors for Treating Frontline CLL

August 29, 2020

During a virtual Case Based Peer Perspectives event, Paul M. Barr, MD, reviewed the case of a 71-year-old woman with newly diagnosed chronic lymphocytic leukemia and the role of BTK inhibitors in the frontline setting.

Portell Discusses the Treatment of Relapsed/Refractory CLL

August 27, 2020

During a virtual Case Based Peer Perspectives event, Craig A. Portell, MD, discussed how he would go about treating a patient case with chronic lymphocytic leukemia.

Burger Reviews BTK Inhibitors and Beyond in Frontline CLL

August 25, 2020

During a virtual Case Based Peer Perspectives event, Jan A. Burger, MD, PhD, discussed testing and the treatment options for chronic lymphocytic leukemia, based on a case of 71-year-old female patient.

Obinutuzumab Triplet Achieves Deep Remissions in Chronic Lymphocytic Leukemia

August 20, 2020

“The regimen of obinutuzumab, ibrutinib, and venetoclax met its primary goal of achieving deep remissions with a fixed-duration combination of targeted agents.”

Expert Highlights Role of BTK Inhibition in Treatment Landscape for CLL

August 18, 2020

In an interview with Targeted Oncology, Jennifer Woyach, MD, discussed the current treatment landscape for patients with chronic lymphocytic leukemia and some of the latest research regarding the BTK inhibitors.

COVID-19 Severity in CLL Correlates With 3 Disease Characteristics

August 18, 2020

The severity of coronavirus disease 2019 increases with age in patients with chronic lymphocytic leukemia. However, age and the existence of comorbidities may not impact death from COVID-19, according to results from a retrospective international study.